The FDA enforcement report dated 2 September lists a Class I recall of Tyenne (tocilizumab-aazg) injection, 400 mg/20 mL vials, manufactured by Fresenius Kabi USA. An internal investigation found glass particles in the product. The recall is ongoing.
Class I is the most serious recall category, used where a product could cause serious harm; particulate matter in an intravenous biologic carries a risk of embolic and infusion-related injury. This is a manufacturing defect in a specific biosimilar product in the US market, not a new safety finding for tocilizumab as a drug. Whether Tyenne is marketed in India, and whether any Indian batches are affected, is not stated; no CDSCO action has been reported.
- This is a US Class I recall of Tyenne 400 mg/20 mL vials for glass particles, not a tocilizumab safety signal.
- Check the brand and lot of any tocilizumab-aazg in stock against the FDA notice.
- Inspect intravenous biologics visually for particles before infusion and use an in-line filter where specified.
- No CDSCO action has been reported for the Indian market.
Why it matters
Particulate contamination of an intravenous biologic can harm patients directly at infusion.
Don't overread it
A manufacturing recall of one biosimilar says nothing about the efficacy or safety of tocilizumab itself.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for rheumatology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free